Compare Entegris Inc (ENTG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Recursion Pharmaceuticals Inc — how do they compare? Entegris Inc trades at $157.69 (market cap $22.95B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.81B). The key difference: Entegris Inc is far larger — about 12.7× Recursion Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ENTG | RXRX | |
|---|---|---|
Market Cap | $22.95B | $1.81B |
Sector | Technology | Health |
52-Week High | $184.00 | $6.79 |
52-Week Low | $68.80 | $2.84 |
Enterprise Value | $26.16B | $1.33B |
Dividend Yield | 0.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $144.21, down 5.17% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $0.93 EPS, driven by AI-related semiconductor demand. Financials show a net income margin of 9.18% and positive operating cash flow of $695.40M in 2025, though valuation ratios like a P/E of 75.11 appear elevated.
Outlook remains positive due to robust earnings growth and AI tailwinds, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $188.67 price target, suggesting 31% upside, supported by institutional buying interest and strong media sentiment from recent news highlights.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
